Philippe Motté as Senior VP, Regulatory and QualityMichiel Hemels as VP, Global Pricing and Market AccessPARIS (BUSINESS WIRE) Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for reti.
Veteran Life Science Executive and New Board Members Bring Deep Expertise to Advance the Company's Enzymatic DNA Synthesis (EDS) Technology and Commercialize its SYNTAX Platform DNA Script, a leader
SEATTLE, Oct. 20, 2021 (GLOBE NEWSWIRE) According to Coherent Market Insights, the global charcot-marie-tooth disease market is estimated to be valued.